Vanadium salt inhibits osteoclast formation and preserves bone integrity in a rat model of type-1 diabetes associated bone loss

IF 4 3区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biometals Pub Date : 2026-04-03 DOI:10.1007/s10534-026-00810-0

Joshua Greendyk, James Thornton, Darian Napoleon, Michael Greenberg, Anthony Lin, Mike Levidy, Jonathan R. Lopez, Maximilian Muñoz, Kevin Innella, Yazan Kadkoy, Maya Deza Culbertson, Jessica A. Cottrell, J. Patrick O’Connor, Joseph Benevenia, David N. Paglia, Sheldon S. Lin

{"title":"Vanadium salt inhibits osteoclast formation and preserves bone integrity in a rat model of type-1 diabetes associated bone loss","authors":"Joshua Greendyk, James Thornton, Darian Napoleon, Michael Greenberg, Anthony Lin, Mike Levidy, Jonathan R. Lopez, Maximilian Muñoz, Kevin Innella, Yazan Kadkoy, Maya Deza Culbertson, Jessica A. Cottrell, J. Patrick O’Connor, Joseph Benevenia, David N. Paglia, Sheldon S. Lin","doi":"10.1007/s10534-026-00810-0","DOIUrl":null,"url":null,"abstract":"<div><p>The effects of vanadyl acetylacetonate (VAC) were evaluated on femur intramedullary osteoclasts in a rat model of type 1 diabetes (T1D) associated bone remodeling. In this study, BB Wistar rats were administered intramedullary injections consisting of either VAC at a dose of 1.5 mg/kg or a control saline solution. These injections were administered at least 12 weeks after the onset of T1D (i.e., treatment began ≥ 12 weeks after diabetes onset) to allow for the establishment of diabetic bone changes. At 4 weeks following treatment, the femurs treated with VAC exhibited a significant increase in trabecular thickness, specifically a 19.03% increase (p < 0.05). Osteoclasts, which were identified using TRAP staining, were found to be reduced in number at both 6 and 8 weeks in the femurs that received VAC treatment (p < 0.05). Likewise, when VAC was added to culture media, it resulted in a substantial decrease in osteoclast formation in vitro (8.1 ± 16.8 vs. 91.6 ± 16.0 cells, p < 0.001). In addition, expression of Dcstamp was significantly decreased in VAC-treated femurs compared to those treated with saline (p < 0.05). Taken together, this study demonstrates that intramedullary VAC delivery appears to inhibit T1D-related bone loss by impairing the process of osteoclastogenesis.</p></div>","PeriodicalId":491,"journal":{"name":"Biometals","volume":"39 5","pages":"1531 - 1543"},"PeriodicalIF":4.0000,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biometals","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1007/s10534-026-00810-0","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The effects of vanadyl acetylacetonate (VAC) were evaluated on femur intramedullary osteoclasts in a rat model of type 1 diabetes (T1D) associated bone remodeling. In this study, BB Wistar rats were administered intramedullary injections consisting of either VAC at a dose of 1.5 mg/kg or a control saline solution. These injections were administered at least 12 weeks after the onset of T1D (i.e., treatment began ≥ 12 weeks after diabetes onset) to allow for the establishment of diabetic bone changes. At 4 weeks following treatment, the femurs treated with VAC exhibited a significant increase in trabecular thickness, specifically a 19.03% increase (p < 0.05). Osteoclasts, which were identified using TRAP staining, were found to be reduced in number at both 6 and 8 weeks in the femurs that received VAC treatment (p < 0.05). Likewise, when VAC was added to culture media, it resulted in a substantial decrease in osteoclast formation in vitro (8.1 ± 16.8 vs. 91.6 ± 16.0 cells, p < 0.001). In addition, expression of Dcstamp was significantly decreased in VAC-treated femurs compared to those treated with saline (p < 0.05). Taken together, this study demonstrates that intramedullary VAC delivery appears to inhibit T1D-related bone loss by impairing the process of osteoclastogenesis.

查看原文本刊更多论文

钒盐抑制破骨细胞形成并保持1型糖尿病相关骨质流失大鼠模型的骨完整性。

在1型糖尿病（T1D）相关骨重塑大鼠模型中，研究了乙酰丙酮钒（VAC）对股骨髓内破骨细胞的影响。在这项研究中，BB Wistar大鼠被给予由1.5 mg/kg剂量的VAC或对照生理盐水溶液组成的髓内注射。这些注射在T1D发病后至少12周进行（即，在糖尿病发病后≥12周开始治疗），以允许糖尿病骨改变的建立。在治疗后4周，经VAC治疗的股骨小梁厚度显著增加，特别是增加19.03% (p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biometals 生物-生化与分子生物学

CiteScore

5.90

自引率

8.60%

发文量

111

审稿时长

3 months

期刊介绍： BioMetals is the only established journal to feature the important role of metal ions in chemistry, biology, biochemistry, environmental science, and medicine. BioMetals is an international, multidisciplinary journal singularly devoted to the rapid publication of the fundamental advances of both basic and applied research in this field. BioMetals offers a forum for innovative research and clinical results on the structure and function of: - metal ions - metal chelates, - siderophores, - metal-containing proteins - biominerals in all biosystems. - BioMetals rapidly publishes original articles and reviews. BioMetals is a journal for metals researchers who practice in medicine, biochemistry, pharmacology, toxicology, microbiology, cell biology, chemistry, and plant physiology who are based academic, industrial and government laboratories.